Search

Your search keyword '"Spielberger, Ricardo"' showing total 79 results
Start Over Author "Spielberger, Ricardo" Search Limiters Academic (Peer-Reviewed) Journals
79 results on '"Spielberger, Ricardo"'

1. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Author

Mei, Matthew, Palmer, Joycelynne, Tsai, Nicole Ni-Chun, Simpson, Jennifer, O'Hearn, James, Stein, Anthony, Forman, Stephen, Spielberger, Ricardo, Cai, Ji-Lian, Htut, Myo, Nakamura, Ryotaro, Al Malki, Monzr M., Herrera, Alex, Wong, Jeffrey, and Nademanee, Auayporn

Published
2023
Full Text
View/download PDF

2. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

Author

Herrera, Alex F, Chen, Lu, Nieto, Yago, Holmberg, Leona, Johnston, Patrick, Mei, Matthew, Popplewell, Leslie, Armenian, Saro, Cao, Thai, Farol, Leonardo, Sahebi, Firoozeh, Spielberger, Ricardo, Chen, Robert, Nademanee, Auayporn, Puverel, Sandrine, Nwangwu, Mary, Lee, Peter, Song, Joo, Skarbnik, Alan, Kennedy, Neena, Peters, Lacolle, Rosen, Steven T, Kwak, Larry W, Forman, Stephen J, and Feldman, Tatyana

Published
2023
Full Text
View/download PDF

3. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Koller, Paul, Tsai, Ni‐Chun, Yang, Dongyun, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Spielberger, Ricardo, Sahebi, Firoozeh, Al Malki, Monzr M., Cai, Ji‐Lian, Sandhu, Karamjeet S., Mansour, Joshua, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, and Marcucci, Guido

Published
2024
Full Text
View/download PDF

4. Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.

Author

Ross, Justine Abella, Lee, Brian, Ma, Huiyan, Tegtmeier, Bernard, Nanayakkara, Deepa, Dickter, Jana, Spielberger, Ricardo, Smith, Eileen, Pullarkat, Vinod, Forman, Stephen J, Taplitz, Randy, Nakamura, Ryotaro, Malki, Monzr Al, and Dadwal, Sanjeet Singh

Abstract

Background Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers despite recommendations to continue prophylaxis through day +75. Characteristics driving AFPx prescribing at hospital discharge and outcomes are unknown. Methods In this retrospective analysis, we reviewed patients continuing AFPx vs no AFPx at hospital discharge. We included patients with a hospital stay ≥7 days and ≤40 days. We excluded patients with a history of IMI prior to alloHCT, new IMI during admission, or death prior to discharge. Our primary objective was incidence of probable or proven IMI per the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Our secondary objectives were nonrelapse mortality at day +100, overall survival at day +100, and characteristics driving AFPx discontinuation at hospital discharge. Results Of the 430 patients identified, 387 met inclusion criteria. At discharge, 56% (217/387) continued AFPx, and 44% (170/387) had no AFPx. At day +100, 3 probable IMI cases occurred in the group with continued AFPx vs 1 probable IMI case in the no-AFPx group (no proven IMI). Univariate analysis showed no difference in cumulative incidence of probable IMI (P =.440), nonrelapse mortality (P =.072), and overall survival (P =.855) between groups. Multivariable logistic regression demonstrated that patients were less likely to continue AFPx if they had a diagnosis other than acute myeloid leukemia, a length of stay ≤30 days, acute graft-vs-host disease grade 0 or 1, and corticosteroid use ≤5 days. Conclusions There was no difference in probable IMI at day +100 after alloHCT based on continuing vs discontinuing AFPx at hospital discharge after alloHCT admission supporting a risk-adapted prophylaxis approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Li, Shanpeng, Zhang, Jianying, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Sahebi, Firoozeh, Sandhu, Karamjeet, Spielberger, Ricardo, Marcucci, Guido, Forman, Stephen J., Stein, Anthony S., Nakamura, Ryotaro, Pullarkat, Vinod, Mei, Matthew, Aldoss, Ibrahim, and Koller, Paul

Published
2024
Full Text
View/download PDF

6. Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis.

Author

Al-Jamaei, Aisha A. H., Epstein, Joel B., de Visscher, Jan G. A. M., Spielberger, Ricardo T., Nakamura, Ryotaro, and Raber-Durlacher, Judith E.

Abstract

Purpose: This study examines the risk of severe oral mucositis (SOM) in graft-versus-host disease prophylaxis (GVHD) compared to other agents in hematopoietic cell transplantation patients. Methods: A comprehensive search of four databases, including PubMed, Embassy, Web of Science, and Scopus, was conducted to identify studies reporting frequency and severity of oral mucositis in association with GVHD prophylactic regimens. RevMan 5.4 was used to perform the meta-analysis. Risk of bias assessment was carried out using the Rob-2 tool for randomized clinical trials (RCTs) and ROBINS-I tool for observational studies. Results: Twenty-five papers, including 11 RCTs and 14 observational studies, met the inclusion criteria. The pooled results from eight RCTs showed a higher risk of SOM in patients receiving MTX or MTX-inclusive GVHD prophylaxis versus non-MTX alternatives (RR = 1.50, 95% CI [1.20, 1.87], I2 = 36%, P = 0.0003). Mycophenolate mofetil (MMF) and post-transplant cyclophosphamide (Pt-Cy) consistently showed lower risk of mucositis than MTX. Folinic acid (FA) rescue and mini-dosing of MTX were associated with reduced oral mucositis severity. Conclusion: Patients receiving MTX have a higher SOM risk compared to other approaches to prevent GVHD, which should be considered in patient care. When appropriate, MMF, FA, and a mini-dose of MTX may be an alternative that is associated with less SOM. This work also underlines the scarcity of RCTs on MTX interventions to provide the best evidence-based recommendations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma.

Author

Othman, Tamer, Baird, John H., Pak, Stacy, Mei, Matthew, Herrera, Alex F., Mansour, Joshua, Shouse, Geoffrey, Sahebi, Firoozeh, Spielberger, Ricardo, Cai, Ji‐Lian, Farol, Leonardo, Godfrey, James, Kallam, Avyakta, Phillips, Tycel, Popplewell, Leslie, Siddiqi, Tanya, Forman, Stephen, and Budde, Lihua E.

Subjects
SKIN cancer, T cells, INFORMED consent (Medical law)
Abstract

This article examines the use of axicabtagene ciloleucel (axi-cel), a CAR T-cell therapy, as a second-line treatment for large B-cell lymphoma (LBCL) in a real-world setting. The study analyzes data from patients who received axi-cel at a single center and evaluates various outcomes such as survival rates, response rates, and side effects. The results indicate that axi-cel is effective and well-tolerated, providing valuable insights for its use in clinical practice. However, larger studies with longer follow-up are needed to further validate its efficacy and practicality. [Extracted from the article]

Published
2024
Full Text
View/download PDF

8. Anti-CD25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma

Author

Herrera, Alex F., Palmer, Joycelynne, Adhikarla, Vikram, Yamauchi, Dave, Poku, Erasmus K., Bading, James, Yazaki, Paul, Dandapani, Savita, Mei, Matthew, Chen, Robert, Cao, Thai, Karras, Nicole, McTague, Pamela, Nademanee, Auayporn, Popplewell, Leslie, Sahebi, Firoozeh, Shively, John E., Simpson, Jennifer, Smith, D. Lynne, Song, Joo, Spielberger, Ricardo, Tsai, Ni-Chun, Thomas, Sandra H., Forman, Stephen J., Colcher, David, Wu, Anna M., Wong, Jeffrey, and Smith, Eileen

Published
2021
Full Text
View/download PDF

10. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Salhotra, Amandeep, Yang, Dongyun, Mokhtari, Sally, Malki, Monzr M. Al, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Mei, Matthew, Budde, Elizabeth, Snyder, David, Cao, Thai, Spielberger, Ricardo, Marcucci, Guido, Pullarkat, Vinod, Forman, Stephen J., Nakamura, Ryotaro, Stein, Anthony, and Aldoss, Ibrahim

Published
2020
Full Text
View/download PDF

11. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

Author

Salhotra, Amandeep, Hui, Susanta, Yang, Dongyun, Mokhtari, Sally, Mei, Matthew, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Dandapani, Savita, Peng, Kelly, Teh, Jennifer Berano, Murata-Collins, Joyce, Budde, Elizabeth, Dadwal, Sanjeet, Pullarkat, Vinod, Snyder, David, Spielberger, Ricardo, Wong, Jeffry, Armenian, Saro, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Stein, Anthony

Published
2020
Full Text
View/download PDF

13. Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission

Author

Stein, Anthony S., Al Malki, Monzr M., Yang, Dongyun, Palmer, Joycelynne M, Tsai, Ni-Chun, Aldoss, Ibrahim, Ali, Haris, Aribi, Ahmed, Artz, Andrew, Dandapani, Savita, Farol, Len, Hui, Susanta, Liu, An, Nakamura, Ryotaro, Pullarkat, Vinod, Radany, Eric, Rosenthal, Joseph, Salhotra, Amandeep, Sanchez, James F, Spielberger, Ricardo, Marcucci, Guido, Forman, Stephen J, and Wong, Jeffrey

Published
2022
Full Text
View/download PDF

16. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia

Author

Stein, Anthony, Palmer, Joycelynne, Tsai, Ni-Chun, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Aribi, Ahmed, Farol, Len, Karanes, Chatchada, Khaled, Samer, Liu, An, O'Donnell, Margaret, Parker, Pablo, Pawlowska, Anna, Pullarkat, Vinod, Radany, Eric, Rosenthal, Joseph, Sahebi, Firoozeh, Salhotra, Amandeep, Sanchez, James F., Schultheiss, Tim, Spielberger, Ricardo, Thomas, Sandra H., Snyder, David, Nakamura, Ryotaro, Marcucci, Guido, Forman, Stephen J., and Wong, Jeffrey

Published
2017
Full Text
View/download PDF

17. Neutropenic ulcers in oncology: terminology, diagnosis, and management.

Author

Güneri, Pelin, Epstein, Joel B., Bolukbasi, Gaye, and Spielberger, Ricardo T.

Abstract

Neutropenic ulcerations are characterized by mucosal ulcerations which occur in the presence of neutropenia, suggesting a direct link between neutropenia and mucosal ulceration. An oral ulcer can be labeled as “neutropenic” only if the patients have primary (typically congenital) or secondary neutropenia, and neutropenia is the sole causative factor. Oral mucosal ulcers observed in patients undergoing oncologic therapy may also be termed as “neutropenic ulcers”, but the pathogenesis of these oral ulcers more likely involves mucosal events related to trauma, microbial factors, and direct cytotoxicity. In cancer patients, the early appearance of oral ulcers is often attributed to oral mucositis which is a condition primarily caused by the direct mucosal cytotoxicity of chemotherapeutic agents and radiation therapy. Oral ulcers that develop later during or after active cancer therapy may result from intraoral trauma and typically manifest on non-keratinized areas of the oral mucosa which are more susceptible to mucosal damage. In patients undergoing chemotherapy, factors such as disturbances in mucosal barrier function as well as bone marrow suppression lead to reduced neutrophil count and function, and can contribute to the development of oral ulcers. While the etiology of oral ulcers in cancer therapy receiving patients can vary, it is important to emphasize that the host’s response plays a crucial role in the progression and repair process of these lesions. This narrative review presents the etiopathogenesis, clinical presentation, and potential management approaches for oral ulcerations in neutropenic patients, with a particular focus on clarifying the usage of the term “neutropenic ulcer” since this term lacks diagnostic specificity and can be misleading in clinical practice regarding the underlying causes and treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.

Author

Aribi, Ahmed, Salhotra, Amandeep, Afkhami, Michelle, Munteanu, Anamaria, Ali, Haris, Aldoss, Ibrahim, Otoukesh, Salman, Al Malki, Monzr M., Sandhu, Karamjeet S., Koller, Paul, Arslan, Shukaib, Stewart, Forrest, Artz, Andrew, Curtin, Peter, Ball, Brian, O'Hearn, James, Spielberger, Ricardo, Smith, Eileen, Budde, Elizabeth, and Nakamura, Ryotaro

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, CANCER chemotherapy, FLUDARABINE
Abstract

We conducted a retrospective analysis of WT1-mutated acute myeloid leukemia (AML) patients who underwent allogeneic stem cell transplant. Thirty-seven patients with WT1-mutated AML were identified. Primary induction failure (40%) and early relapse rate (18%) after idarubicin/cytarabine (7 + 3) chemotherapy were observed. All patients with induction failure subsequently achieved CR with additional chemotherapy. There was no significant difference between outcomes after myeloablative vs. reduced intensity (Fludarabine/Melphalan [Flu/Mel]) conditioning regimens. RFS but not OS was significantly better in patients who received FLAG-IDA prior to transplant and/or a fludarabine-containing conditioning. In an independent ex vivo study, WT1-mutated AML samples exhibited greater sensitivity to fludarabine (p = 0.026) and melphalan (p = 0.0005) than non-WT1-mutated AML samples while there was no difference between sensitivity to cytarabine. Our data favor using a fludarabine-based induction for AML with WT1 mutation instead of 7 + 3. Fludarabine conditioning regimens for alloHCT showed better RFS but not OS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma.

Author

Ong, Shin Yeu, Pak, Stacy, Mei, Matthew, Wang, Yan, Popplewell, Leslie, Baird, John H., Herrera, Alex F., Shouse, Geoffrey, Nikolaenko, Liana, Zain, Jasmine, Godfrey, James, Htut, Myo, Aribi, Ahmed, Spielberger, Ricardo, Mansour, Joshua, Forman, Stephen J., Palmer, Joycelynne, and Budde, Lihua E.

Published
2023
Full Text
View/download PDF

20. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies

Author

Aldoss, Ibrahim, Yang, Dongyun, Malki, Monzr M. Al, Mei, Matthew, Mokhtari, Sally, Artz, Andrew, Cao, Thai, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Khaled, Samer, Arslan, Shukaib, Sandhu, Karamjeet, Koller, Paul, Mansour, Joshua, Spielberger, Ricardo, Stein, Anthony, Snyder, David, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2021
Full Text
View/download PDF

22. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.

Author

Mei, Matthew, Palmer, Joycelynne, Ni-Chun Tsai, Nicole, Simpson, Jennifer, O'Hearn, James, Stein, Anthony, Forman, Stephen, Spielberger, Ricardo, Cai, Ji-Lian, Htut, Myo, Nakamura, Ryotaro, Malki, Monzr M. Al, Herrera, Alex, Wong, Jeffrey, and Nademanee, Auayporn

Published
2023
Full Text
View/download PDF

30. Palifermin for oral mucositis after intensive therapy for hemotologic cancers

Author

Spielberger, Ricardo, Bensinger, William, Stiff, Patrick, Gentile, Teresa, Kewalramani, Tarun, dorf, Daniel, Shea, Thomas, Hansen, Keith, Yanovich, Saul, Noga, Stephen, Sung, Eric C., LeMaistre, C. Frederick, McCarthy, John, Blazar, Bruce, Emmanouilides, Christos, Mon-Gy Chen, and Elhardt, Dieter

Subjects
Chemotherapy -- Health aspects, Blood diseases -- Risk factors, Blood diseases -- Care and treatment, Oral mucosa -- Risk factors, Oral mucosa -- Care and treatment, Cancer -- Chemotherapy, Cancer -- Health aspects
Abstract

The ability of palifermin is tested to decrease oral mucosal injury induced by cytotoxic therapy was tested. It was found that palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.

Published
2004

31. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Author

Nademanee, Auayporn, Forman, Stephen, Molina, Arturo, Fung, Henry, Smith, David, Dagis, Andy, Kwok, Cheuk, Yamauchi, Dave, Anderson, Anne-Line, Falk, Peter, Krishnan, Amrita, Kirschbaum, Mark, Kogut, Neil, Nakamura, Ryotaro, O'Donnell, Margaret, Parker, Pablo, Popplewell, Leslie, Pullarkat, Vinod, Rodriguez, Roberto, Sahebi, Firoozeh, Smith, Eileen, Snyder, David, Stein, Anthony, Spielberger, Ricardo, Zain, Jasmine, White, Christine, and Raubitschek, Andrew

Published
2005
Full Text
View/download PDF

33. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

Author

Lopez, Francisco, Parker, Pablo, Nademanee, Auayporn, Rodriguez, Roberto, Al-Kadhimi, Zaid, Bhatia, Ravi, Cohen, Sandra, Falk, Peter, Fung, Henry, Kirschbaum, Mark, Krishnan, Amrita, Kogut, Neil, Molina, Arturo, Nakamura, Ryotaro, O’Donnell, Margaret, Popplewell, Leslie, Pullarkat, Vinod, Rosenthal, Joseph, Sahebi, Firoozeh, Smith, Eileen, Snyder, David, Somlo, George, Spielberger, Ricardo, Stein, Anthony, Sweetman, Robert, Zain, Jasmine, and Forman, Stephen

Published
2005
Full Text
View/download PDF

36. Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma

Author

Nademanee, Auayporn, Molina, Arturo, Dagis, Andrew, Snyder, David S., O'Donnell, Margaret R., Parker, Pablo, Stein, Anthony, Smith, Eileen, Planas, Ina, Kashyap, Ashwin, Spielberger, Ricardo, Fung, Henry, Krishnan, Amrita, Bhatia, Ravi, Wong, K.K., Somlo, George, Margolin, Kim, Chow, Warren, Sniecinski, Irene, Vora, Nayana, Slovak, Marilyn, Niland, Joyce C., and Forman, Stephen J.

Published
2000
Full Text
View/download PDF

38. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission

Author

Nademanee, Auayporn, Molina, Arturo, Fung, Henry, Stein, Anthony, Parker, Pablo, Planas, Ina, O'Donnell, Margaret R., Snyder, David S., Kashyap, Ashwin, Spielberger, Ricardo, Bhatia, Ravi, Krishnan, Amrita, Sniecinski, Irena, Vora, Nayana, Slovak, Marilyn, Dagis, Andrew, Niland, Joyce C., and Forman, Stephen J.

Published
1999
Full Text
View/download PDF

39. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma

Author

Margolin, Kim A, Van Besien, Koen, Wright, Christine, Niland, Joyce, Champlin, Richard, Fung, Henry C, Kashyap, Ashwin, Molina, Arturo, Nademanee, Auayporn P, O'Donnell, Margaret R, Parker, Pablo, Smith, Eileen, Spielberger, Ricardo, Somlo, George, Snyder, David, Stein, Anthony, Woo, Doni, Thomas, Michael, Sneicinski, Irena, and Forman, Stephen J

Published
1999
Full Text
View/download PDF

40. Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant.

Author

Pourmoussa, Andrew Mayer, Spielberger, Ricardo, Jilian Cai, Khoshbin, Odelia, Farol, Leonardo, Thai Cao, and Sahebi, Firoozeh

Subjects
*STEM cell transplantation, *HEMATOPOIETIC stem cells, *MULTIPLE myeloma, *PROGNOSIS, *HEMATOPOIETIC stem cell transplantation
Abstract

Introduction: Despite advances in therapy for multiple myeloma, patients have continued to experience relapse. We sought to better understand this. Objective: To identify factors that predict early relapse in patients with multiple myeloma who receive autologous hematopoietic peripheral stem cell transplant (HSCT). Methods: Retrospective analysis of Kaiser Permanente Southern California patients who received HSCTs between 2008 and 2012. Results: A total of 141 patients were included. Factors found to be associated with inferior progression-free survival were disease status less than complete response at the time of HSCT, no use of maintenance therapy after HSCT, International Staging System stage III, and high Freiburg Comorbidity Index. Disease status less than complete response, stage III, higher Freiburg Comorbidity Index, no use of maintenance therapy, and male sex were the most predictive factors for early relapse (< 18 months). Discussion: Our results identified a subgroup of high-risk individuals with multiple myeloma who will continue to do poorly after HSCT with the best available treatment using a combination of proteasome inhibitors and immunomodulatory drugs. These results highlight the need for consideration of alternative therapy in such instances. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL).

Author

Sandhu, Karamjeet S., Quy Huynh-Tran, Cooper, Elise Elise, Jianying zhang, Palmer, Joycelynne, Ni-Chun Tsai, Thomas, Sandra, Robbins, Marjorie, Aribi, Ahmed, Salhotra, Amandeep, Mei, Mathew, Ji-Lian Cai, Spielberger, Ricardo, Koller, Paul, Aldoss, Ibrahim, Stein, Anthony, Marcucci, Guido, and Budde, L. Elizabeth

Published
2021
Full Text
View/download PDF

45. Poster: ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL).

Author

Sandhu, Karamjeet S., Huynh-Tran, Quy, Cooper, Elise Elise, Zhang, Jianying, Palmer, Joycelynne, Tsai, Ni-Chun, Thomas, Sandra, Robbins, Marjorie, Aribi, Ahmed, Salhotra, Amandeep, Mei, Mathew, Cai, Ji-Lian, Spielberger, Ricardo, Koller, Paul, Aldoss, Ibrahim, Stein, Anthony, Marcucci, Guido, and Budde, L. Elizabeth

Published
2021
Full Text
View/download PDF

47. Entrainment of Ventricular Tachycardia by Sinus Rhythm.

Author

Kremers, Mark S., Levine, Benjamin, Spielberger, Ricardo, and Passos-Coelho, Jose

Subjects
TACHYCARDIA, HEART diseases, HEART ventricles, CARDIAC pacing, ARRHYTHMIA, DRUGS
Abstract

Entrainment of ventricular tochycardia (VT) may be manifest as fixed and progressive QRS fusion with ventricular and, rarely, atrial pacing. Only a single example of spontaneous VT entrainment by another rhythm, rapid atrioventricular nodal tachycardia, has been reported. This article describes an example of fixed and progressive QRS fusion between conducted sinus rhythm and VT consistent with entrainment. In contrast to entrainment with pacing, entrainment of VT by sinus rhythm occurred with drug-mediated arrhythmia slowing and demonstrated progressive QBS fusion at a constant cycle length. However, it did not demonstrate unfused but entrained QRS complexes. The resulting short PB interval and wide QRS mimicked a preexcited rhythm. [ABSTRACT FROM AUTHOR]

Published
1989
Full Text
View/download PDF

50. Concomitant Amphotericin B Therapy, Granulocyte Transfusions, and GM-CSF Administration for Disseminated Infection with Fusarium in a Granulocytopenic Patient.

Author

Spielberger, Ricardo T., Falleroni, Marc J., Coene, Amy J., and Larson, Richard A.

Abstract

The use of granulocyte transfusions during amphotericin B treatment of invasive fungal infections in granulocytopenic patients is controversial because of concern about pulmonary complications from leukostasis. Moreover, the administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) to patients with active infections has been questioned because of reports that this cytokine inhibits neutrophil migration into areas of inflammation. We report a case in which the combined use of amphotericin B, granulocyte transfusions, and GM-CSF was safe and life-saving in a pancytopenic patient with disseminated fusarium infection. Histologic evidence of the migration of neutrophils into an area of active infection was found. [ABSTRACT FROM PUBLISHER]

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results